UTMD · XBRL financial data

Utah Medical Products financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (UTMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	42,178	49,054	52,281	50,224	40,903	38,520
Cost of goods and services sold	16,630	18,137	20,085	20,186	16,760	16,519
Gross profit	25,548	30,917	32,196	30,038	24,143	22,001
Research and development	486	526	493	560	813	668
General and administrative	9,800	10,097	10,406	11,016	7,835	7,880
Operating income (loss)	13,708	18,880	19,790	16,777	13,594	11,402
Other income (expense)	0	0	188	256	(174)	(120)
Income tax expense (benefit)	3,042	4,273	4,186	3,454	2,928	2,824
Earnings per share, basic USD per share	2.95	4.05	4.53	4.58	3.96	3.48
Earnings per share, diluted USD per share	2.94	4.04	4.52	4.57	3.96	3.48
Weighted average shares, basic thousands of shares	3,658	3,647	3,637	3,629	3,503	3,240
Weighted average shares, diluted thousands of shares	3,672	3,660	3,643	3,637	3,503	3,240

Fiscal years (UTMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	51,590	60,974	75,052	92,868	82,976	85,756
Accounts receivable	4,104	5,132	5,538	3,391	4,094	3,522
Inventory	6,222	6,596	8,814	9,582	8,812	7,935
Total current assets	62,262	73,158	89,919	106,269	96,330	97,742
Property and equipment, net	11,326	11,067	10,224	10,551	9,763	9,908
Right-of-use asset	377	449	395	342	338	286
Goodwill	14,164	14,098	13,354	13,692	13,580	14,052
Total assets	111,745	115,636	123,874	135,458	122,538	122,542
Accounts payable	788	761	1,218	769	696	911
Accrued liabilities	3,003	2,984	4,742	3,941	3,061	1,687
Total current liabilities	3,791	3,745	5,960	4,710	3,757	2,598
Lease liability, non-current	335	396	341	295	282	226
Total liabilities	8,923	8,498	9,620	7,145	5,111	3,274
Retained earnings	110,952	115,314	126,006	138,341	129,302	128,652
Total stockholders' equity	102,822	107,138	114,254	128,313	117,427	119,268
Total liabilities and equity	111,745	115,636	123,874	135,458	122,538	122,542
Common shares outstanding (cover page) thousands of shares	3,646	3,655	3,628	3,589	3,282	3,185

Fiscal years (UTMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Stock-based compensation	160	166	183	225	256	373
Net cash from operating activities	20,137	21,203	21,147	22,281	14,831	14,692
Purchases of property and equipment	860	552	809	639	230	371
Net cash from investing activities	(860)	(552)	(818)	(639)	(208)	(371)
Proceeds from issuing common stock	358	560	174	117	390	0
Share repurchases	6,976	0	2,495	0	19,968	8,355
Dividends paid	4,116	11,465	3,163	4,282	4,260	3,983
Net cash from financing activities	(10,734)	(10,905)	(5,484)	(4,165)	(23,838)	(12,338)
Net change in cash	8,803	9,384	14,078	17,816	(9,892)	2,780

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Utah Medical Products	87,528	8,529	1,383*	3.2M	—	Q2 FY26 10-QJun 30, 2026
SkinHealth Systems	206,074	72,113	2,671*	130.1M	—	Q2 FY26 10-QJun 30, 2026
Sight Sciences	77,402	24,923	(2,402)*	55.6M	15.2 quarters	Q3 FY26 10-QSep 30, 2026
Profound Medical	38,271	2,483	(11,338)*	36.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Stereotaxis	10,491	7,670	(3,675)*	100.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Inogen	87,276	95,084	2,946*	26.5M	—	Q2 FY26 10-QJun 30, 2026
Semler Scientific	10,176	7,491	(32,950)*	15.2M	0.3 quarters	Q3 FY25 10-QSep 30, 2025
Sanara MedTech	15,421	28,137	2,038*	9.2M	—	Q2 FY26 10-QJun 30, 2026
Anika Therapeutics	38,412	32,610	(684)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.